Skip to content

Transcranial Direct Current Stimulation (tDCS) and Anorexia Nervosa

Measuring the Effect of a Program of 20 Sessions of Transcranial Direct Current Stimulation With 2 Milli-ampere Targeting the Dorsolateral Prefrontal Cortex on the Symptoms of Anorexia Nervosa: An Open Label Uncontrolled Pilots Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02734108
Acronym
STAR
Enrollment
10
Registered
2016-04-12
Start date
2016-01-06
Completion date
2018-05-02
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa

Keywords

Sever anorexia nervosa

Brief summary

Anorexia nervosa is an eating disorder characterized by intense fear of becoming fat despite the obvious thinness and extreme behaviors for weight loss. The result is a massive weight loss and / or pathological thinness. The care of anorexia is difficult and few treatments have proved to be effective in adults. Transcranial direct current stimulation (tDCS) is a neuromodulation technique that uses an electrical current of low intensity. It allows to modulate the corticospinal excitability: two electrodes, an anode (excitatory) and a cathode (inhibitory), are positioned on the skull according to the region which is desired to influence the operation. Although tDCS was shown to no noticeable side effects, it is first necessary to assess the feasibility and safety of this technique in these physically frail patients. A recent pilot study suggests the acceptability, safety and efficacy of tDCS program in patients with anorexia nervosa. Given these preliminary data and the extreme seriousness and vulnerability of patients with resistant anorexia, the investigators want to assess the risk / benefit ratio for the use of this technique in patients suffering from resistant anorexia nervosa. The current data are too preliminary to consider a randomized controlled trial, the investigators hope, initially, replicate the data from this pilot study in a second sample with a more rigorous and comprehensive assessment methodology .

Detailed description

During stimulation, the anode will be placed over the left dorsolateral prefrontal cortex and the cathode on the right dorsolateral prefrontal cortex. Stimulation of 2 milli-Ampere is applied for 25 minutes each session. 20 sessions will be conducted twice a day respecting a period of four hours between sessions. The tDCS sessions will start maximum 15 days after the inclusion visit. Two intermediate control visits will be conducted. One after the first week of tDCS, the other immediately after the last session of tDCS. The main assessment visit will be carried out one month (+/- 5 days) after the last session of tDCS. Finally a reminder visit will be performed 6 months (+/- 3 weeks) after the last session of tDCS to assess the stability over time of the potential effects observed.

Interventions

DEVICETranscranial direct current stimulation

Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Present a current anorexia nervosa (according to Diagnostic and Statistical Manual of Mental Disorders (DSM V)) ,severe, for at least 3 years * Attest to the failure of at least one outpatient treatment conducted by a specialized team (Level 2/3) for the management of patients with eating disorders according to the criteria of French Association for the Development of Specialized Approaches of eating disorders and General Direction of the care * Have an effective mean of contraception throughout the study * Being able to understand the nature, purpose and methodology of the study * Being affiliated to a social security scheme or being the beneficiary of such a scheme. * Having signed the informed consent

Exclusion criteria

* Refusal to participate * Present a body mass index lower than 13.5 * Present a history of seizures or epilepsy * Presenting a head injury and / or brain pathology * Presenting an unstabilized serious physical illness * Present pregnancy (attested by a blood test Beta-HCG) or breastfeeding * Present physical disease that may affect cognitive abilities and brain structures (eg HIV infection, multiple sclerosis, lupus, Parkinson's disease, epilepsy, dementia ...) * Deprived of liberty subject (judicial or administrative decision) * People protected by law

Design outcomes

Primary

MeasureTime frameDescription
Evolution of the Eating Disorders Examination Questionnaire (EDEq) scoreAt the baseline and 1 month after the last session of tDCSComparison between the total score of the Eating Disorders Examination Questionnaire (EDEq) 28 days before tDCS program and 28 days after the end of a program of 20 sessions of tDCS with 2 milliampere targeting dorsolateral prefrontal cortex

Secondary

MeasureTime frameDescription
Evolution of depressive symptoms assessed by patients with Beck Depression Inventory (BDI) questionnaireAt the baseline, the end of the first and second week of stimulation, 1 month and 6 months after the last session of tDCSEvaluate the evolution of mood as an associated symptoms of anorexia nervosa
Evolution of depressive symptoms assessed by the psychiatrist by Montgomery Asberg Depression Rating Scale (MADRS)At the baseline, 1 month and 6 months after the last session of tDCSEvaluate the evolution of mood as an associated symptoms of anorexia nervosa
Evolution of mania symptoms assessed by the physician with Young Mania Rating Scale (YMRS)At the baseline, the end of the first and second week of stimulation, 1 month and 6 months after the last session of tDCSEvaluate the evolution of mood as an associated symptoms of anorexia nervosa
Evolution of the Exercise Dependence Scale (EDS-R) scoreAt the baseline, 1 month and 6 months after the last session of tDCSEvaluate the evolution of physical activity as an associated symptoms of anorexia nervosa
Evolution of the Global Physical Activity Questionnaire (GPAQ) scoreAt the baseline, 1 month and 6 months after the last session of tDCSEvaluate the evolution of physical activity as an associated symptoms of anorexia nervosa
Evolution of the Maudsley Obsessive Compulsive Inventory (MOCI) scoreAt the baseline, 1 month and 6 months after the last session of tDCSEvaluate the evolution of obsessiveness as an associated symptoms of anorexia nervosa sensitivity
Evolution of the sensitivity to punishment and sensitivity reward questionnaireAt the baseline, 1 month and 6 months after the last session of tDCSEvaluate the evolution of reward sensitivity as an associated symptoms of anorexia nervosa sensitivity
Number of participants with treatment-related adverse events assessed by tDCS adverse effect questionnaireAt the end of the first and second week of stimulationEvaluate the safety of this program: side effects, early termination of the patient, acceptability
Evolution of the neuropsychological performance measured with the Iowa Gambling Task (IGT)At the baseline and 1 month after the last session of tDCSEvaluate the evolution of neuropsychological performance as an associated symptoms of anorexia nervosa sensitivity
Evolution of the neuropsychological performance measured with the Brixton testAt the baseline and 1 month after the last session of tDCSEvaluate the evolution of neuropsychological performance as an associated symptoms of anorexia nervosa sensitivity
Evolution of the neuropsychological performance measured with the Rey-Osterrieth Complex FigureAt the baseline and 1 month after the last session of tDCSEvaluate the evolution of neuropsychological performance as an associated symptoms of anorexia nervosa sensitivity
Evolution of the neuropsychological performance measured with the D2 testAt the baseline and 1 month after the last session of tDCSEvaluate the evolution of neuropsychological performance as an associated symptoms of anorexia nervosa sensitivity
Evolution of the patient's level of function measured with the Work and Social Adjustment Scale (WSAS)6 monthsEvaluate the evolution of the patient's level of function as an associated symptoms of anorexia nervosa sensitivity
Evolution of the patient's level of function measured with the Global Assessment of Functioning (GAF)6 monthsEvaluate the evolution of the patient's level of function as an associated symptoms of anorexia nervosa sensitivity
Evolution of the neuropsychological performance measured with the National Adult Reading Test (NART)At the baseline and 1 month after the last session of tDCSEvaluate the evolution of neuropsychological performance as an associated symptoms of anorexia nervosa sensitivity

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026